CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells

Neoplasia

Volumn 11, Issue 12, 2009, Pages 1309-1317

  Roca, Hernan ^a,b   Varsos, Zachary S ^a,b   Pienta, Kenneth J ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISINDOLYLMALEIMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B INHIBITOR; PROTEIN P70; SERINE; SURVIVIN; THREONINE;

ARTICLE; CANCER CELL; CELL DEATH; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LETHALITY; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; SERUM; SIGNAL TRANSDUCTION; STARVATION;

EID: 72949121254     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09936     Document Type: Article

References (50)

1. Birnbaum MJ (2005). Activating AMP-activated protein kinase without AMP. Mol Cell 19, 289-290.
2. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG, and Hardie DG (2005). Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2, 9-19.
3. Meijer AJ and Codogno P (2007). AMP-activated protein kinase and autophagy. Autophagy 3, 238-240.
4. Meijer AJ and Dubbelhuis PF (2004). Amino acid signalling and the integration of metabolism. Biochem Biophys Res Commun 313, 397-403.
5. Meley D, Bauvy C, Houben-Weerts JH, Dubbelhuis PF, Helmond MT, Codogno P, and Meijer AJ (2006). AMP-activated protein kinase and the regulation of autophagic proteolysis. J Biol Chem 281, 34870-34879.
6. Harris TE and Lawrence JC Jr (2003). TOR signaling. Sci STKE 2003, re15.
7. Papandreou I, Lim AL, Laderoute K, and Denko NC (2008). Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell Death Differ 15, 1572-1581.
8. Hardie DG (2007). AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8, 774-785.
9. Hardie DG and Sakamoto K (2006). AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology (Bethesda) 21, 48-60.
10. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, and Shaw RJ (2008). AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30, 214-226.
11. Sabatini DM (2006). mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6, 729-734.
12. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, and Yonezawa K (2002). Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-189.
13. Wang L, Harris TE, Roth RA, and Lawrence JC Jr (2007). PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 282, 20036-20044.
14. Codogno P and Meijer AJ (2005). Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ 12 (Suppl 2), 1509-1518.
15. Cuervo AM (2004). Autophagy: in sickness and in health. Trends Cell Biol 14, 70-77.
16. Reggiori F and Klionsky DJ (2005). Autophagosomes: biogenesis from scratch? Curr Opin Cell Biol 17, 415-422.
17. Viana R, Aguado C, Esteban I, Moreno D, Viollet B, Knecht E, and Sanz P (2008). Role of AMP-activated protein kinase in autophagy and proteasome function. Biochem Biophys Res Commun 369, 964-968.
18. Mizushima N and Yoshimori T (2007). How to interpret LC3 immunoblotting. Autophagy 3, 542-545.
19. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, and Yoshimori T (2000). LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19, 5720-5728.
20. Bar-Shavit Z (2007). The osteoclast: a multinucleated, hematopoietic-origin, boneresorbing osteoimmune cell. J Cell Biochem 102, 1130-1139.
21. Charo IF and Taubman MB (2004). Chemokines in the pathogenesis of vascular disease. Circ Res 95, 858-866.
22. Pienta KJ and Loberg R (2005). The "emigration, migration, and immigration" of prostate cancer. Clin Prostate Cancer 4, 24-30.
23. Talmadge JE, Donkor M, and Scholar E (2007). Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 26, 373-400.
24. Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, and Pienta KJ (2006). CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8, 578-586.
25. Roca H, Varsos Z, and Pienta KJ (2008). CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem 283, 25057-25073.
26. Roca H, Varsos ZS, Mizutani K, and Pienta KJ (2008). CCL2, survivin and autophagy: new links with implications in human cancer. Autophagy 4, 969-971.
27. Burnett PE, Barrow RK, Cohen NA, Snyder SH, and Sabatini DM(1998). RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 95, 1432-1437.
28. Hoyer-Hansen M, Bastholm L, Szyniarowski P, Campanella M, Szabadkai G, Farkas T, Bianchi K, Fehrenbacher N, Elling F, Rizzuto R, et al. (2007). Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol Cell 25, 193-205.
29. Carling D (2004). The AMP-activated protein kinase cascade - a unifying system for energy control. Trends Biochem Sci 29, 18-24.
30. Hardie DG (2004). The AMP-activated protein kinase pathway - new players upstream and downstream. J Cell Sci 117, 5479-5487.
31. Kosaka T, Okuyama R, SunW, Ogata T, Harada J, Araki K, Izumi M, Yoshida T, Okuno A, Fujiwara T, et al. (2005). Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry. Anal Chem 77, 2050-2055.
32. Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, and Roth RA (2003). Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem 278, 10189-10194.
33. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, and Sabatini DM (2007). PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25, 903-915.
34. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108, 1167-1174.
35. Thimmaiah KN, Easton JB, Germain GS, Morton CL, Kamath S, Buolamwini JK, and Houghton PJ (2005). Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem 280, 31924-31935.
36. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, and Hay N (2005). Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280, 32081-32089.
37. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, and Dyck JR (2003). Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem 278, 39422-39427.
38. Marmy-Conus N, Hannan KM, and Pearson RB (2002). Ro 31-6045, the inactive analogue of the protein kinase C inhibitor Ro 31-8220, blocks in vivo activation of p70(s6k)/p85(s6k): implications for the analysis of S6K signalling. FEBS Lett 519, 135-140.
39. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-PerretT, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F, et al. (1991). The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266, 15771-15781.
40. Klionsky DJ (2007). Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 8, 931-937.
41. Mizushima N, Levine B, Cuervo AM, and Klionsky DJ (2008). Autophagy fights disease through cellular self-digestion. Nature 451, 1069-1075.
42. Levine B (2007). Cell biology: autophagy and cancer. Nature 446, 745-747.
43. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, Domingo D, and Yahalom J (2001). A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61, 439-444.
44. Maiuri MC, Zalckvar E, Kimchi A, and Kroemer G (2007). Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8, 741-752.
45. S6 kinase. Autophagy 1, 59-60; discussion 60-1.
46. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, and Carling D (2007). Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J 403, 139-148.
47. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, and Cantley LC (2004). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101, 3329-3335.
48. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, and Cantley LC (2004). The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99.
49. Marignani PA (2005). LKB1, the multitasking tumour suppressor kinase. J Clin Pathol 58, 15-19.
50. Wei C, Amos CI, Stephens LC, Campos I, Deng JM, Behringer RR, Rashid A, and Frazier ML (2005). Mutation of Lkb1 and p53 genes exert a cooperative effect on tumorigenesis. Cancer Res 65, 11297-11303. Lung Carcinoma Cells1,2